🇺🇸 FDA
Patent

US 12357586

Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

granted A61KA61K31/05A61K31/19

Quick answer

US patent 12357586 (Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy) held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Grant date
Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/05, A61K31/19, A61K31/352, A61K31/4015